2-Cyano-thioacetimidic acid 4-methoxy-benzyl ester | 252004-23-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-Cyano-thioacetimidic acid 4-methoxy-benzyl ester
• 英文别名: (4-methoxyphenyl)methyl 2-cyanoethanimidothioate
• CAS: 252004-23-2
• 化学式: C₁₁H₁₂N₂OS
• 分子量: 220.295
• InChiKey: JWBCGELUZPPPNB-UHFFFAOYSA-N

物化性质

• 沸点：
  368.3±52.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  82.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Cyano-thioacetimidic acid 4-methoxy-benzyl ester 在 吡啶 、 碘 作用下， 生成 [4-cyano-3-(4-methoxy-benzylsulfanyl)-isothiazol-5-yl]-carbamic acid phenyl ester
  参考文献：
  名称：

  Discovery of novel isothiazole inhibitors of the TrkA kinase: Structure–activity relationship, computer modeling, optimization, and identification of highly potent antagonists

  摘要：

  The design, synthesis, and biological evaluation of potent inhibitors of the TrkA kinase is presented. A homology model is created to aid in the enhancement of potency and selectivity of isothiazole inhibitors found during a high-throughput screen. Three different syntheses are utilized to make diverse analogs within this series. Aminoheterocycles are found to be good urea surrogates, whereas bicyclic substituents on the C3 thio group were found to be extremely potent TrkA inhibitors in kinase and cell assays. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.003
• 作为产物：
  描述：

  4-甲氧基苄硫醇 、 丙二腈 生成 2-Cyano-thioacetimidic acid 4-methoxy-benzyl ester
  参考文献：
  名称：

  Discovery of novel isothiazole inhibitors of the TrkA kinase: Structure–activity relationship, computer modeling, optimization, and identification of highly potent antagonists

  摘要：

  The design, synthesis, and biological evaluation of potent inhibitors of the TrkA kinase is presented. A homology model is created to aid in the enhancement of potency and selectivity of isothiazole inhibitors found during a high-throughput screen. Three different syntheses are utilized to make diverse analogs within this series. Aminoheterocycles are found to be good urea surrogates, whereas bicyclic substituents on the C3 thio group were found to be extremely potent TrkA inhibitors in kinase and cell assays. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.003

文献信息

• [EN] ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS<br/>[FR] DERIVES ISOTHIAZOLE UTILES EN TANT QU'AGENTS ANTICANCEREUX
  申请人：PFIZER PRODUCTS INC.

  公开号：WO1999062890A1

  公开（公告）日：1999-12-09

  (EN) The present invention relates to compounds of formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.(FR) La présente invention concerne des composés correspondant à la formule (1), ainsi que des sels, promédicaments et solvates de ces composés, acceptables sur le plan pharmacologique. Dans cette formule, X1, R1, R2 et R3 possèdent les notations données dans la description. L'invention concerne également des compositions pharmaceutiques contenant les composés ci-dessus, ainsi que des méthodes de traitement de troubles hyperproliférants, chez des mammifères, consistant à administrer les composés ci-dessus.

  (中) 本发明涉及公式（1）的化合物和其药学上可接受的盐、前药和溶剂化物，其中X1、R1、R2和R3如本文所定义。本发明还涉及包含上述化合物的制药组合物以及通过给予上述化合物治疗哺乳动物的增殖过度性疾病的方法。
• Isothiazole derivatives useful as anticancer agents
  申请人：——

  公开号：US20010020034A1

  公开（公告）日：2001-09-06

  The present invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X 1 , R 1 , R 2 and R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.

  本发明涉及式子11的化合物，以及其药学上可接受的盐、前药和溶剂化物，其中X1、R1、R2和R3如本文所定义。本发明还涉及包含上述化合物的药物组合物，以及通过给予上述化合物治疗哺乳动物的过度增殖性疾病的方法。
• Isothiazole Derivatives Useful as Anticancer Agents
  申请人：Larson Eric R.

  公开号：US20080300249A1

  公开（公告）日：2008-12-04

  The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X 1 , R 1 , R 2 and R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.

  本发明涉及公式1的化合物及其药学上可接受的盐、前药和溶剂化物，其中X1、R1、R2和R3的定义如本文所述。本发明还涉及包含上述化合物的制药组合物以及通过给予上述化合物治疗哺乳动物的增殖过度性疾病的方法。
• ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Pfizer Products Inc.

  公开号：EP1084114B1

  公开（公告）日：2004-09-08
• US6235764B1
  申请人：——

  公开号：US6235764B1

  公开（公告）日：2001-05-22